<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="infections despite aggressive management, additional treatment with antiviral drugs (e.g.," exact="plerixafor" post="and/or zidovudine) can be considered. Cats with no identifiable"/>
 <result pre="for treatment of HIV infection [13]. The anti-FIV activity of" exact="zidovudine" post="has been assessed in numerous in vitro studies in"/>
 <result pre="carried out in 1989, when North and coworkers showed that" exact="zidovudine" post="inhibited FIV replication in Crandell-Rees feline kidney (CRFK) cells."/>
 <result pre="Crandell-Rees feline kidney (CRFK) cells. The susceptibility of FIV to" exact="zidovudine" post="was similar to that of HIV [27]. There is"/>
 <result pre="the FIV gene is responsible for resistance [10]. In vivo," exact="zidovudine" post="can reduce plasma viral load, improve the immunologic and"/>
 <result pre="of life, and prolong life expectancy [16]. In placebo-controlled trials," exact="zidovudine" post="improved stomatitis and increased the CD4/CD8 ratio in naturally"/>
 <result pre="bone marrow suppression. Regular blood cell counts are necessary during" exact="zidovudine" post="treatment because non-regenerative anemia is a common side effect"/>
 <result pre="not be treated with zidovudine. Most FIV-infected cats treated with" exact="zidovudine" post="for as long as two years tolerated the drug"/>
 <result pre="in vitro [18,19,20,23,26,35,36]. Mutants of FIV that are resistant to" exact="stavudine" post="and cross-resistant to several other antivirals, including zidovudine, have"/>
 <result pre="is active against FIV in vitro [3,20,21,23,38,41]. A combination of" exact="zidovudine" post="and lamivudine had synergistic anti-FIV activities in cell cultures"/>
 <result pre="against FIV in vitro [3,20,21,23,38,41]. A combination of zidovudine and" exact="lamivudine" post="had synergistic anti-FIV activities in cell cultures [41]. FIV"/>
 <result pre="anti-FIV activities in cell cultures [41]. FIV mutants resistant to" exact="lamivudine" post="and containing a point mutation in the RT gene"/>
 <result pre="gene were selected in vitro and showed cross resistance to" exact="zidovudine" post="[23]. In one in vivo study, experimentally FIV-infected cats"/>
 <result pre="the cats with this high-dose dual-drug treatment [41]. Thus, high-dose" exact="lamivudine" post="treatment alone, or in combination with zidovudine, is not"/>
 <result pre="cats. 2.5. Emtricitabine Emtricitabine (2',3'-deoxy-5-fluoro-3'-thiacytidine, FTC) is structurally similar to" exact="lamivudine" post="and was licensed by the FDA in 2003 [40]."/>
 <result pre="had higher levels of cytotoxicity than other compounds, such as" exact="didanosine" post="and amdoxovir [16,20]. There are no in vivo studies"/>
 <result pre="only approved NtARTi for the treatment of HIV infection is" exact="tenofovir" post="disoproxil fumarate (TDF), the prodrug of tenofovir ((R)-9-(2-phosphonylmethoxypropyl)adenine, (R)-PMPA),"/>
 <result pre="HIV infection is tenofovir disoproxil fumarate (TDF), the prodrug of" exact="tenofovir" post="((R)-9-(2-phosphonylmethoxypropyl)adenine, (R)-PMPA), which is also a member of the"/>
 <result pre="of the acyclic nucleoside phosphonates [43,45]. The antiviral spectrum of" exact="tenofovir" post="(2R-1-(6-amino-9H-purin-9-yl)-propan-2-yl-oxy-methyl-phosphonic acid, PMPA) is narrower than that of adefovir;"/>
 <result pre="thereby preventing nucleotide synthesis [66]. Others, such as ribavirin, inhibit" exact="inosine" post="monophosphate dehydrogenase after intracellular phosphorylation, which in turn leads"/>
 <result pre="variety of DNA and RNA viruses [71]. Systemic administration of" exact="ribavirin" post="is limited in cats because of side effects [72]."/>
 <result pre="limited in cats because of side effects [72]. Sequestration of" exact="ribavirin" post="within erythrocytes results in hemolysis, even when low doses"/>
 <result pre="primarily on megakaryocytes, resulting in thrombocytopenia and hemorrhage. With prolonged" exact="ribavirin" post="treatment or at higher doses, the production of erythrocytes"/>
 <result pre="induce hepatic toxicity. An attempt to decrease the toxicity of" exact="ribavirin" post="by incorporating it into lecithin-containing liposomes and administering it"/>
 <result pre="vivo because of toxicity [74]. To date, the efficacy of" exact="ribavirin" post="has not been investigated in FIV-infected cats. 6. Receptor"/>
 <result pre="placebo-controlled double-blinded clinical trial, treatment of naturally FIV-infected cats with" exact="plerixafor" post="resulted in a significant decrease in proviral load in"/>
 <result pre="any clinical consequences. Development of resistance of FIV isolates to" exact="plerixafor" post="did not occur during treatment [53]. In cats, plerixafor"/>
 <result pre="to plerixafor did not occur during treatment [53]. In cats," exact="plerixafor" post="is administered at a dosage of 0.5 mg/kg every"/>
 <result pre="and further studies are needed to investigate the potential of" exact="tipranavir" post="in naturally infected cats. 7.2. Lopinavir Lopinavir (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhex-an-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide) is"/>
 <result pre="as an anti-HIV compound. Similar to lopinavir, some efficacy of" exact="atazanavir" post="was shown against FIV in vitro, but there are"/>
 <result pre="FIV in vitro [92], but FIV was less susceptible to" exact="raltegravir" post="than HIV [92]. No studies in FIV-infected cats exist"/>
 <result pre="there are no in vivo studies on the efficacy of" exact="raltegravir" post="in FIV-infected cats, the drug recently was shown to"/>
 <result pre="feline immunodeficiency virus infection: Part 1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of" exact="zidovudine" post="(ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in"/>
 <result pre="virus infection: Part 1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of zidovudine (ZDV)," exact="lamivudine" post="(3TC) and abacavir (ABC) antiretroviral therapy in suppressing in"/>
 <result pre="1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of zidovudine (ZDV), lamivudine (3TC) and" exact="abacavir" post="(ABC) antiretroviral therapy in suppressing in vitro FIV replicationAntivir."/>
 <result pre="inhibitors for the treatment of HIV: A brief history of" exact="stavudine" post="(D4T) and its comparison with other dideoxynucleosidesAntivir. Res.201085343810.1016/j.antiviral.2009.10.00619854224 35.BalzariniJ.EgberinkH.HartmannK.CahardD.VahlenkampT.ThormarH.de"/>
 <result pre="Immunol. Immunopathol.19923515516610.1016/0165-2427(92)90128-D1337395 53.HartmannK.StengelC.KleinD.EgberinkH.BalzariniJ.Efficacy and adverse effects of the antiviral compound" exact="plerixafor" post="in feline immunodeficiency virus-infected catsJ. Vet. Intern. Med./Am. Coll."/>
 <result pre="kinetic analysesProtein Sci.2007161728173710.1110/ps.07282900717656585 56.DasK.MartinezS.E.BaumanJ.D.ArnoldE.HIV-1 reverse transcriptase complex with DNA and" exact="nevirapine" post="reveals non-nucleoside inhibition mechanismNat. Struct. Mol. Biol.20121925325910.1038/nsmb.222322266819 57.AuwerxJ.NorthT.W.PrestonB.D.KlarmannG.J.De ClercqE.BalzariniJ.Chimeric"/>
 <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistanceCurr. Opin. Virol.20148101510.1016/j.coviro.2014.04.01124846716 72.LafeuilladeA.HittingerG.ChadapaudS.Increased mitochondrial toxicity with ribavirin in"/>
 <result pre="basis of ribavirin resistanceCurr. Opin. Virol.20148101510.1016/j.coviro.2014.04.01124846716 72.LafeuilladeA.HittingerG.ChadapaudS.Increased mitochondrial toxicity with" exact="ribavirin" post="in HIV/HCV coinfectionLancet200135728028110.1016/S0140-6736(00)03618-711214134 73.PoveyR.C.Effect of orally administered ribavirin on"/>
 <result pre="toxicity with ribavirin in HIV/HCV coinfectionLancet200135728028110.1016/S0140-6736(00)03618-711214134 73.PoveyR.C.Effect of orally administered" exact="ribavirin" post="on experimental feline calicivirus infection in catsAm. J. Vet."/>
 <result pre="calicivirus infection in catsAm. J. Vet. Res.19783913371341697143 74.WeissR.C.CoxN.R.BoudreauxM.K.Toxicologic effects of" exact="ribavirin" post="in catsJ. Vet. Pharmacol. Ther.19931630131610.1111/j.1365-2885.1993.tb00177.x8230401 75.WeissR.C.CoxN.R.MartinezM.L.Evaluation of free or"/>
 <result pre="in catsJ. Vet. Pharmacol. Ther.19931630131610.1111/j.1365-2885.1993.tb00177.x8230401 75.WeissR.C.CoxN.R.MartinezM.L.Evaluation of free or liposome-encapsulated" exact="ribavirin" post="for antiviral therapy of experimentally induced feline infectious peritonitisRes."/>
 <result pre="antagonistBlood20031022728273010.1182/blood-2003-02-066312855591 85.NorelliS.El DakerS.D’OstilioD.MeleF.ManciniF.TagliaF.RuggieriA.CiccozziM.CaudaR.CiervoA.et al.Response of feline immunodeficiency virus (FIV) to" exact="tipranavir" post="may provide new clues for development of broad-based inhibitors"/>
 <result pre="Res.2007536538810.2174/15701620778102396517627500 89.MouscadetJ.F.AroraR.AndreJ.LambryJ.C.DelelisO.MaletI.MarcelinA.G.CalvezV.TchertanovL.HIV-1 in alternative molecular recognition of DNA induced by" exact="raltegravir" post="resistance mutationsJ. Mol. Recognit.20092248049410.1002/jmr.97019623602 90.CattoriV.WeibelB.LutzH.Inhibition of feline leukemia virus"/>
 <result pre="of the effect of short-term treatment with the integrase inhibitor" exact="raltegravir" post="(Isentress) on the course of progressive feline leukemia virus"/>
 <result pre="type-I interferon on retrovirusesViruses2009154557310.3390/v103054521994560 100.ZeidnerN.S.MylesM.H.Mathiason-DuBardC.K.DreitzM.J.MullinsJ.I.HooverE.A.Alpha interferon (2β) in combination with" exact="zidovudine" post="for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency"/>
</results>
